May 3rd 2024
During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a patient with hormone receptor–positive breast cancer after progression in the first article of a 2-part series.
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Show Me Your Care Plan: Nursing Considerations for Managing Breast Cancer Patients
View More
Community Practice Connections™: The Newest Frontier in HR+ Breast Cancer—Targeting ESR1 Mutations with Next-Generation Endocrine Therapy
View More
Clinical Case Vignette Series™: 40th Annual Miami Breast Cancer Conference®
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
HER2+ Breast Cancer Tumor Board: Navigating Current and Evolving Strategies from Early Stages to Metastases
View More
Show Me the Data®: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® West
July 12-13, 2024
Register Now!
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Community Practice Connections®: Evaluating the Evolving Treatment Landscape for mHR+ Breast Cancer-How to Personalize Care and Improve Patient Outcomes
View More
Community Practice Connections™: Leveraging Multidisciplinary Teams in Early-Stage Breast Cancer When the Goal Is Cure
View More
Community Practice Connections™: 22nd Annual International Congress on the Future of Breast Cancer®
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
22nd Annual School of Breast Oncology
November 7-9, 2024
Register Now!
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Dr. Amanda Kong on High Versus Low Volume Hospitals in the Treatment of Breast Cancer
December 21st 2015​Amanda L. Kong, MD, MS, FACS, discusses breast cancer care at high volume hospitals versus low volume hospitals. Kong says the study is the first one that looks at processes as a bundle and takes into account socioeconomic statuses of patients.
Watch
Dr. Clifford A. Hudis on the Importance of In-Breast Response Rates in Triple-Negative Breast Cancer
December 17th 2015Clifford A. Hudis, MD, FACP, Vice President for Government Relations and Chief Advocacy Officer, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center, discusses carboplatin in triple-negative breast cancer and in-breast response rates.
Watch
Survival Improved Over 10 Years With Breast-Conserving Therapy Versus Mastectomy
December 15th 2015Breast-conserving therapy (BCT) and radiation in early-stage breast cancer has been shown to give patients about a 20% better chance of survival over the course of 10 years, moreso than their counterparts who opted had mastectomy.
Read More
Dr. Carey Anders on Treating Brain Metastases in Breast Cancer
December 15th 2015Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, UNC Chapel Hill, on the challenge of treating brain metastases in breast cancer. Anders says brain metastases generally portend a poor prognosis and treatment for them are currently scarce.
Watch
Study Links pCR Post-Neoadjuvant Therapy to Increased Survival Rates in TNBC
December 15th 2015Treatment with standard neoadjuvant chemotherapy plus carboplatin and/or bevacizumab resulting in a pathologic complete response has been associated with improvement in event-free and overall survival in patients with triple-negative breast cancer.
Read More
Breast Cancer Survival Increased by Earlier Adjuvant Chemotherapy
December 14th 2015A team of researchers with the University of Texas MD Anderson Cancer Center found that adjuvant chemotherapy has a significant impact on patient survival, especially in patients with triple-negative breast cancer.
Read More
Denosumab Shows Survival Boost in Postmenopausal Women
December 11th 2015A follow-up benefits analysis of adding denosumab to aromatase inhibitor (AI) therapy shows the agent not only helps prevent fractures, it also reduces risk of recurrence and death in postmenopausal women with HR-positive breast cancer.
Read More
FDA Gives Palbociclib Priority Review for Pretreated HR-Positive/HER2-Negative Breast Cancer
December 10th 2015Palbociclib (Ibrance) has been given a priority review by the FDA. The treatment will be looked at as a combination with fulvestrant in pretreated patients with HR-positive, HER2-negative metastatic breast cancer, said Pfizer, the manufacturer of the CDK 4/6 inhibitor.
Read More
Adjuvant Capecitabine Boosts Survival Rates in HER2-Negative Breast Cancer
December 10th 2015A combination of capecitabine and adjuvant therapy dropped the risk of recurrence by 30% and prolonged survival by 40% for patients with residual breast cancer post-neoadjuvant chemotherapy and surgery, according to phase III data.
Read More
HER2+ Breast Cancer Treatment Future May Lie in Adjuvant Therapies
November 25th 2015Therapies in the adjuvant setting like trastuzumab (Herceptin) and neratinib have shown more durable responses in patients with HER2+ breast cancer, as opposed to long-term treatment, said Mohammad Jahanzeb, MD.
Read More
Next-Generation Sequencing in Contralateral Breast Cancer Could Affect Treatment Decisions
November 23rd 2015A new method to elucidate the clonal relationship between tumors used tissues and clinical details from patients with contralateral breast cancer, and for the first time, next-generation sequencing.
Read More
Dr. Howard A. Burris, III, on Modern Chemotherapy for Patients with HER2-Positive Breast Cancer
November 20th 2015Howard A. "Skip" Burris, III, MD, president, Clinical Operations, chief medical officer and executive director of Drug Development, Sarah Cannon, talks about chemotherapy in the era of personalized medicine.
Watch
Dr. Mohammad Jahanzeb on Neratinib and Trastuzumab in HER2-Positive Breast Cancer
November 19th 2015Mohammad Jahanzeb, MD, medical director, Sylvester Comprehensive Cancer Center at Deerfield Beach, talks about the future of treatment for patients with HER2-positive breast cancer with drugs like neratinib and trastuzumab.
Watch
Despite the small size of the pigeon brain, our Columba livia counterparts have performed just as well as humans in distinguishing between normal tissue and breast cancer tissue in a study performed by researchers at the University of Iowa and the University of California, Davis.
Read More